Effectiveness of Dexamethasone and Hyaluronidase + Valerate of Bethasone Associated with Prepucial Massage in the Treatment of Child Phimosis Volume 2 - Issue 1

Charles Azuwike Odoemene*

• Alex Ekwueme Federal University Teaching Hospital, Nigeria

Received: June 24, 2019;   Published: July 08, 2019

Corresponding author: Charles Azuwike Odoemene, Senior Lecturer/Consultant Urologist, Alex Ekwueme Federal University Teaching Hospital, Abakaliki (AEFUTHA), Nigeria

DOI: 10.32474/JUNS.2019.02.000131

Abstract PDF

1. Hamid RAH, Tendi W, Sesari SS, Mochtar CA, Umbas R, et al. (2019) The importance of targeting intracrinology in prostate cancer management World. J Urol 37: 751.
2. Yeboah ED, Quartey JKM (1997) Low dosage stilboestrol in the management of carcinoma of the prostate.Ghana Med J p. 13-15.
3. Nkposong EO, Lawani J (1983) Primary carcinoma of the prostate in Ibadan. W Afr Med J 22: 108-111.
4. Attah C (1989) Pattern and management of urinary tract cancers among Nigerian Igbos.Int. Urol and Nephro 21: 449-454.
5. Magoha GAO (2000) Management and survival in advanced prostate cancer in Nairobi. East Afr Med J 77: 260-263.
6. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, et al. (2013) GLOBOCAN 2012 VIO, Cancer incidence mortality worldwide”, IARC cancer base II. International agency for research.
7. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, et al. (2015) Cancer incidence and mortality worldwide; Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: 359-386.
8. Huggins C, Hodges CV (1941) Studies on prostate cancer 1; The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297.
9. Lin YH, Chen CL, Hou CP, Chang PL, Tsui KH, et al. (2011) A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma. Acta pharmacologica Sinica 32: 537-542.
10. Masaki S, Masatashi E (2016) Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone sensitive prostate cancer. Int J Urol 23: 360-369.
11. Salmasi AH, Patel N, Yi-Kim I (2016) Androgen deprivation therapy; Appropriate patients timing to initiate ADT and complications. In: mydlo JH, Godec CJ (Eds.), Prostate cancer science and clinical practice (2^nd edn), 481-489.
12. Raghavan RP, Purushothaman A, Kumar GP, Gangadharan P (2016) A comparison of leuprolide acetate versus bilateral orchiectomy for patients with metastatic prostate cancer. Asian J Pharm Clin Res 9: 51-54.
13. Zhang K, Zhang L, Hao Z, Liang C (2016) Androgen deprivation therapy for prostate cancer; friend or foe to the cardiovascular system. World J Urol 34: 879-881.
14. Conndly RM, Carducci AM, Antonraki ES (2012) Use of androgen deprivation therapy in prostate cancer, indications and prevalence. Asian J Androl 14: 177-186.
15. Cowey CL, Hutson T (2013) Management of newly diagnosed metastatic disease. In: Klein EA, Jones JS, (Eds.), Current clinical urology. springer science. pp. 361-378.
16. Miyamotor H, Messing EM, Chang C (2004) Androgen deprivation therapy for prostate cancer; current status and future prospects. Prostate 61: 332-353.
17. Raj GV, Seith LA, Day TK, Tilley WD (2015) Evolution of androgen deprivation therapy. Cancer Forum 39: 189-194.
18. De Paula AP, Piccelli HR, Pinto NP, Tele AG, Franqueiro AG, et al. (2003) Economic impact of orchiectomy for advanced prostate cancer. Int braz j urol 29: 127-132.
19. Labrie F (2011) Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol 8: 73-80.
20. Heinlen CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25(2): 276-308.
21. Lee RJ, Smith MR (2016) Initial systemic therapy for castration sensitive prostate cancer.
22. Bott SRJ, Birtle AJ, Taylor CJ, Kirby RS (2003) Prostate cancer management: (2) an update on locally advanced and metastatic disease. Postgrad Med J 79(937): 643-645.
23. Catolana WJ (2017) Hormonal therapy explained.
24. Rud O, Peter J, Kheyri R, Gilfrich C, Ahmed AM, et al. (2012) Sub capsular orchiectomy in the primary therapy of patients with bone metastasis in advanced prostate cancer: An anachronistic intervention? Advances in urol 2012: 190624,
25. Theyer G, Ulsperger E, Baumgartner G, Raderer M, Hamilton G (2000) Prolonged response to a single androgen suppression phase in a subpopulation of prostate cancer patients. Annals of oncology 11: 877-881.
26. d’Ancona FCH, Debruyne FMJ (2005) Endocrine approaches in the therapy of prostate carcinoma. Human Reproduction Update 11: 309-317.
27. Tai Lung C (2015) Chemo-hormonal therapy for metastatic hormone sensitive prostate cancer: clinical trial fantasy or practice reality? Urological science 26: 223-224.
28. Oken M, Creech RH, Tormey DC, Horton J, Davis TE, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655.
29. Raiput R, Seghal A (2012) Endocrine manipulations in cancer prostate: A review. Indian J Endocrinol Metab 16(supll 2): S199-S204.
30. Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, et al. (2014) Androgen receptor antagonists for prostate cancer therapy. Endocrn Relat Cancer 21: T105-T118.
31. Pope AJ, Abel PD (2010) Androgen deprivation therapy for prostate cancer and its complications. Trends in Urol Gynaecol and sexual health 15: 32-37.
32. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, et al. (2014) Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. The prostate 74: 210-216.
33. Wallace TJ, Torre T, Grob M, Yu J, Avital I, et al. (2014) Current approaches challenges and future directions for monitoring treatment response in prostate cancer. J Cancer 5: 3-24.
34. Wong K W, Ma W K, Wong C W (2016) Impact of skeletal related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy. Hongkong Med J 22: 106-115.
35. Pederson EA, Shiozawa Y, Pienta KJ, Taichman RS (2012) The prostate cancer bone marrow niche: more than just “fertile soil”. Asian J Androl 14: 423-427.
36. Tsuzuki S, Park S H, Eber M R, Shiozawa Y (2016) Skeletal complications in cancer patients with bone metastasis. Int J Urol 23: 825-832.
37. Merseburger A S, Hupe M C (2016) An update on Triptorelin: current thinking on androgen deprivation therapy for prostate cancer. Adv. Ther 33: 1072-1093.
38. Ang M, Raicic B, Foreman D, O Callaghan ME (2016) Men presenting with prostate specific antigen (PSA) values of over 100ng/ml. BJU Int 112(suppl 4): 68-75.
39. Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP (2013) The utility of prostate specific antigen in the management of advanced prostate cancer. BJU Int 112: 548-560.
40. Fitzpatrick JM, Banu E, Oudard S (2009) Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int 103: 578-587.
41. Rosario DJ, Davey P, Green J, Greene D, Turner B, et al. (2016) The role of gonadotrophin-releasing hormone antagonist in the treatment of patients with advanced hormone dependent prostate cancer in the UK. World J Urol 34: 1601-1609.
42. Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, et al. (2010) Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarilix 80mg versus leuprolide in prostate cancer patients segmented y base line characteristics. Eur Urol 57: 836-842.
43. Hussain M, Tangen C M, Higano C, Schelhammer PF, Faulkner J, et al. (2006) Absolute prostate -specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastic prostate cancer; data from south west Oncology Group trial 9346 (INT-0162). J Clin Oncology 24: 3984-3990.
44. Hussain MHA, Goldman B, Tangen C, Higano CS, Petrylak DP, et al. (2009) Prostate-specific antigen survival in patients with metastatic prostate cancer: data from south west Oncology Group trials 9346 (intergroup study 0162 and 9916). J Clin Oncol 27: 2450-2456.
45. Lin G W, Yao X D, Zhang S L, Dai B, Ma CG, et al. (2009) Prostate specific antigen half-life a new predictor of progression free survival and overall survival in Chinese prostate cancer patients. Asian J Androl 11: 443-450.
46. Hanninen M, Venner P, North S (2009) A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. J Can Urol Asoc 3: 369-374.
47. Demir A, Cecen K, Karadag MA, Kocaaslan R, Turkeri L (2014) The course of metastatic prostate cancer under treatment. Springerplus 3: 725.
48. Shahani S, Braga-Basaria M, Maggio M, Basaria S (2009) Androgens and erythropoiesis past and present. J Endocrinol Invest 32: 704-716.
49. Rodriguez vida A, Choudry S, Chouldry S (2014) Management of fatigue and anemia in men treated with androgen deprivation therapy. Trends in Urology and Men’s health 5: 25-28.
50. Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff P W, et al. (2015) Adverse effect of androgen deprivation therapy and strategies to mitigate them. European Urology 67: 825-836.
51. Vargas A, Machado RD, Filho DI, Paiva CE, Dos Reis RB, et al. (2016) LHRH analog is associated with worse metabolic sie effects than bilateral orchiectomy in prostate cancer. World J Urol 34: 1621-1628.
52. Jeating NL, O’Mally A, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular diseases during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl of Cancer Inst 102: 39-46.
53. Alibhai SM, Duong Hua M, Sutradhar R, Fleshner NE, Warde P, et al. (2009) Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 27: 3452-3458.
54. Rivera Arkoncel M, Sagun M, Arkoncel F, Jimeno C, Lapitan M (2014) Prevalence of diabetes mellitus and metabolic syndrome in prostate cancer patients given androgen deprivation therapy. Journal of the ASEAN Federation of Endocrine Societies 29: 42.
55. Teoh JY, Chiu PK, Chan Sm Y, Poon DM, Cheung HY, et al. (2015) Risk of new onset diabetes after androgen deprivation therapy in the Asian population. J Diabetes 7: 672-680.
56. Oka H, Negoro H, Sugino Y, Iwamura H, Moroi S, et al. (2003) Change of serum adrenal androgens in prostatic cancer patients after bilateral orchiectomy or LHRH agonist treatment. Hinyokika Kiyo 49: 521-525.
57. Chauhan S, Collins K, Kruga M, Diamond MP (2004) Effect of gonadotrophin releasing hormone hypogonedism on insulin action as assessed by hyperglycemic clamp studies in Men. Fertile Steril 84: 109-1098.
58. Bienz M, Saad F (2015) Androgen deprivation therapy and bone loss in prostate cancer patients: a clinical review. BoneKey Rep 4: 716.
59. Nagao K, Matsuyama H, Nozawa M, Hara I, Nishioka T, et al. (2016) Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients - A propensity scoring approach. Asian journal of urology 3(1): 33-38.
60. Cheung AS, Zaiac JD, Grossmann M (2014) Muscle and bone effect of androgen deprivation therapy: current and emerging therapies. Endocr Relat Cancer 21: R371-R394.
61. Hamilton EJ, Ghasem Zadeh A, Gianatti E, Lim Joon D, Bolton D, et al. (2010) Structural decay of bone micro architecture in men with prostate cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab 95: E456-E463.
62. Sharifi N, Gulley JI, Dahut WI (2005) Androgen depivation therapy for prostate cancer. JAMA 294: 238-244.
63. Udoh E, Oisaeke F (2015) Our experience with prostate cancer patients who presented with side effect of androgen deprivation therapy (Adt) since 2007 and review of literature. Asian J Biomedical research 1: 2454-6275.
64. Sun M, Choueiri T K, Hamnvik O P, Preston M A, De Velasco G, et al. (2016) Comparism of Gonadotropin Releasing hormone Agonists and Orchiectomy:Effects of Androgen deprivation therapy. JAMA Oncol 2: 500-507.
65. Ibrahim AG, Aliyu S, Dogo HM, Tahir MB, Zarami AB (2015) Orchidectomy as the primary therapy in patients with advanced carcinoma of the prostate: A ten year experience in Maiduguri North Eastern Nigeria. I JAR 1: 515-517.
66. Krahn M, Bremner KE, Tomlinson G, Luo J, Ritvo P, et al. (2011) Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use? BJU Int 108: 1588-1596.
67. Cassileth BR, Soloway MS, Vogelzang NJ, Schellhammer PS, Seidmon EJ, et al. (1989) Patient’s choice of treatment in stage D prostate cancer. Urology 33(5 suppl): 57-62.